Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in squamous cell carcinoma of the tongue: Markers of nerve invasion?

被引:10
|
作者
Doumas S. [1 ,2 ]
Paterson J.C. [3 ]
Norris P.M. [1 ]
Tighe J.V. [1 ]
Newman L. [1 ]
Bisase B.S. [1 ]
Kolokotronis A.E. [4 ]
Barrett A.W. [1 ,5 ]
机构
[1] Queen Victoria Hospital NHSF Trust, East Grinstead, West Sussex
[2] Southern General Hospital, Glasgow
[3] UCL Advanced Diagnostics, London
[4] Oral Medicine & Maxillofacial Pathology, Dental School, Aristotle University, Thessaloniki
[5] Department of Histopathology, Queen Victoria Hospital NHSF Trust, Holtye Road, East Grinstead
关键词
Fractalkine; Fractalkine receptor; Oral cancer; Perineural invasion;
D O I
10.1007/s10006-014-0455-4
中图分类号
学科分类号
摘要
Conclusions: Neither fractalkine nor fractalkine receptor is a reliable surrogate marker of PNI in lingual SCC.; Purpose: Perineural invasion (PNI) in oral squamous cell carcinoma (SCC) is an independent predictor of poor prognosis. As PNI is not always identified with routine histology, a surrogate marker of PNI would improve detection and better inform treatment planning. The chemokines fractalkine (CX3CL1) and its receptor (CX3CR1) have shown such potential in other cancers, but have yet to be investigated with respect to PNI in oral SCC.; Results: Both markers labelled myofibroblasts in the stroma surrounding the tumour, various neural components, leucocytes, endothelium and salivary myoepithelial cells. Fractalkine also labelled salivary ductal epithelium, vascular smooth muscle and 12/30 SCC which showed PNI. Eight of 30 positive SCCs in which PNI was not identified were also positive for this marker. There was no statistically significant association between fractalkine staining and PNI (p = 0.273). No SCC was positive for fractalkine receptor, but immune dendritic cells within tumour islands were strongly positive, as was striated muscle.; Methods: Thirty SCCs of the tongue in which PNI was identified histologically, and 30 in which it was not, were stained for fractalkine and fractalkine receptor using polyclonal antibodies and an immunoperoxidase technique. Tumours were assessed as either positive or negative; no attempt was made to subjectively assess staining intensity or extent. © 2014, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:61 / 64
页数:3
相关论文
共 50 条
  • [1] Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease
    Patel, A.
    Jagadesham, V. P.
    Porter, K. E.
    Scott, D. J. A.
    Carding, S. R.
    [J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2008, 36 (01) : 20 - 27
  • [2] Expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the trigeminal ganglia: implications for craniofacial nociception
    Gazerani, P.
    Cairns, B. E.
    Dong, X. D.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2014, 15
  • [3] Role of fractalkine/CX3CL1 and its receptor CX3CR1 in allergic diseases
    Julia, Valerie
    Staumont-Salle, Delphine
    Dombrowicz, David
    [J]. M S-MEDECINE SCIENCES, 2016, 32 (03): : 260 - 266
  • [4] Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue
    Hosokawa, Y
    Nakanishi, T
    Yamaguchi, D
    Nakae, H
    Matsuo, T
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 139 (03): : 506 - 512
  • [5] EVALUATION OF THE ROLE OF FRACTALKINE CHEMOKINE CX3CL1 AND ITS RECEPTOR CX3CR1 IN INFLAMMATORY MYOPATHIES
    Colafrancesco, S.
    Priori, R.
    Astorri, E.
    Scrivo, R.
    D'Amati, G.
    Giordano, C.
    Valesini, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 568 - 568
  • [6] Fractalkine, (CX3CL1)/fractalkine receptor (CX3CR1) interactions influence motor and sensory recovery after spinal cord injury
    McDaniel, EE
    Popovich, PG
    [J]. JOURNAL OF NEUROTRAUMA, 2005, 22 (10) : 1219 - 1219
  • [7] The Chemokine CX3CL1 (Fractalkine) and its Receptor CX3CR1: Occurrence and Potential Role in Osteoarthritis
    Wojdasiewicz, Piotr
    Poniatowski, Lukasz A.
    Kotela, Andrzej
    Deszczynski, Jaroslaw
    Kotela, Ireneusz
    Szukiewicz, Dariusz
    [J]. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2014, 62 (05) : 395 - 403
  • [8] The Chemokine CX3CL1 (Fractalkine) and its Receptor CX3CR1: Occurrence and Potential Role in Osteoarthritis
    Piotr Wojdasiewicz
    Łukasz A. Poniatowski
    Andrzej Kotela
    Jarosław Deszczyński
    Ireneusz Kotela
    Dariusz Szukiewicz
    [J]. Archivum Immunologiae et Therapiae Experimentalis, 2014, 62 : 395 - 403
  • [9] EHMTI-0062. Expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the trigeminal ganglia: implications for craniofacial nociception
    P Gazerani
    BE Cairns
    XD Dong
    [J]. The Journal of Headache and Pain, 2014, 15
  • [10] Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis
    Hasegawa, M
    Sato, S
    Echigo, T
    Hamaguchi, Y
    Yasui, M
    Takehara, K
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) : 21 - 28